China’s Pharmaceutical Industry – Rapid Growth and Global Standards
Over the past decade, China has implemented a series of regulatory reforms that have reshaped the pharmaceutical landscape. These reforms have transformed China’s pharmaceutical ecosystem, enhanced R&D efficiency through streamlined development cycles, and increased capital flows to biopharmaceutical innovation and growing penetration of globally developed treatments. Growth in Drug Innovation in China:In 2024, 93 innovative drugs were approved for the first time in China, the highest number in a decade. Of these, 42% were developed locally. Over the past decade, China’s share of globally first-approved innovative drugs has steadily increased, surpassing Japan and Europe in 2021 to become the second-largest region for first approvals. Investment and Industry Growth:Over the past decade, China’s biopharmaceutical sector has attracted more than 418.4 billion Chinese yuan in primary market financing. Investment peaked in 2021 with 103.4 billion Chinese yuan raised across 811 financing events, with the majority directed toward small molecule drugs (34%), cell therapies (21%), and therapeutic vaccines (12%). Globalization of Chinese Companies:Responding to intense local competition and constrained financing since 2021, Chinese pharmaceutical companies have accelerated globalization strategies to maintain growth. Between 2015 and 2024, the number of outbound licensing deals increased significantly, with 94 deals completed in 2024 alone, bringing the total potential value of cumulative deals to $51.9 billion USD.